AbSci (ABSI)
NASDAQ:ABSI
Want to see ABSI full AI Analyst Report?
ABSI Stock Chart & Stats
$3.58
$0.12(3.91%)
At close: 4:00 PM EST
$3.58
$0.12(3.91%)
Day’s Range― - ―
52-Week Range$2.24 - $5.67
Previous CloseN/A
Volume51.94M
Average Volume (3M)4.08M
Market Cap
$873.61M
Enterprise Value$858.89M
Total Cash (Recent Filing)$144.29M
Total Debt (Recent Filing)$5.30M
Price to Earnings (P/E)―
Beta2.25
Next Earnings
May 19, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding155,447,430
10 Day Avg. Volume3,710,040
30 Day Avg. Volume4,082,116
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.52
Price to Sales (P/S)170.48
P/FCF Ratio-5.08
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue306.75
Enterprise Value/Gross Profit-23.31
Enterprise Value/Ebitda-7.60
Forecast
1Y Price Target
$7.64Price Target Upside113.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.79
Revenue Forecast (FY)$9.02M
Bulls Say, Bears Say
Bulls Say
Business Strategy And PlatformOrigin-1 generative AI combined with a shift to out-licensing individual assets could accelerate lead discovery, attract partnership economics, and leverage cash resources to advance multiple programs efficiently.
Clinical TrialsAn interim multiple-dose proof-of-concept readout from the HEADLINE study could provide the first clinical efficacy signal and guide expansion into a Phase 2 study for endometriosis, representing a major inflection if positive.
Mechanism Of ActionABS-201's prolactin-blocking mechanism is supported by human scalp follicle and ex vivo data that suggest prolonged hair growth and the potential to outperform existing topical treatments, offering a differentiated therapeutic approach.
Bears Say
Data Limitations And Investor PerceptionLimited human data on prolactin-targeting and the single-dose trial focus on safety rather than efficacy may sustain investor skepticism until meaningful efficacy readouts emerge.
Development RiskEarly clinical-stage status leads analysts to apply a conservative probability of success, leaving material uncertainty until patient efficacy data are available.
Financial PerformanceQuarterly results showing revenue below expectations and a wider loss per share could strain near-term financial flexibility and weigh on investor sentiment.
AbSci News
ABSI FAQ
What was AbSci’s price range in the past 12 months?
AbSci lowest stock price was $2.24 and its highest was $5.67 in the past 12 months.
What is AbSci’s market cap?
AbSci’s market cap is $873.61M.
When is AbSci’s upcoming earnings report date?
AbSci’s upcoming earnings report date is May 19, 2026 which is in 14 days.
How were AbSci’s earnings last quarter?
AbSci released its earnings results on Mar 24, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.178 by -$0.022.
Is AbSci overvalued?
According to Wall Street analysts AbSci’s price is currently Undervalued.
Does AbSci pay dividends?
AbSci does not currently pay dividends.
What is AbSci’s EPS estimate?
AbSci’s EPS estimate is -0.2.
How many shares outstanding does AbSci have?
AbSci has 155,447,430 shares outstanding.
What happened to AbSci’s price movement after its last earnings report?
AbSci reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.178. Following the earnings report the stock price went down -2.99%.
Which hedge fund is a major shareholder of AbSci?
Currently, no hedge funds are holding shares in ABSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbSci Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.64 (113.41% Upside)
$7.64 (113.41% Upside)
Blogger Sentiment
Neutral
ABSI Sentiment 50%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $96.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.2%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
15.85%
12-Months-Change
Fundamentals
Return on Equity
-59.68%
Trailing 12-Months
Asset Growth
1.26%
Trailing 12-Months
Company Description
AbSci
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
ABSI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial progress and multiple near-term catalysts: first-in-human dosing for ABS-201 with favorable emerging safety/PK, an expanded indication into endometriosis with a planned Phase 2, published platform validation for de novo antibody design, strong survey-based commercial interest, and a stated cash runway into 2028. Counterbalancing these positives are modest current revenue, increased R&D spend (+37.5% YoY for the quarter), a sequential cash decline (-5.4%), early-stage clinical evidence with limited exposure, and competitive/regulatory uncertainties. On balance, the momentum on clinical advancement, platform differentiation, and market interest outweigh the present financial burn and early-stage risks.View all ABSI earnings summariesABSI Stock 12 Month Forecast
Average Price Target
$7.64
▲(113.41% Upside)
Technical Analysis
Autolus Therapeutics
―
―
ADC Therapeutics
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
6.65% Insiders
20.23% Mutual Funds
1.23% Other Institutional Investors
51.09% Public Companies and
Individual Investors